Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells
Current Oncology · 2025
DOI: 10.3390/curroncol32110607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Gülşah Altun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sivas Numune State Hospital, 58060 Sivas, Türkiye. Hauptthemen laut MEDLINE: Bevacizumab, Sorafenib, Carcinoma, Neuroendocrine, Thyroid Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Medullary thyroid carcinoma is a rare neuroendocrine tumor with limited therapeutic options, as current kinase inhibitors are often associated with significant toxicity and drug resistance. This study aimed to explore novel treatment strategies by testing targeted agents alone and in combination.
Methods
Human medullary thyroid carcinoma TT cells with RET mutations were treated with Sorafenib, Lapatinib, and Bevacizumab. Cell proliferation was monitored in real time using the xCELLigence system, and apoptosis was assessed by flow cytometry.
Results
Sorafenib and Lapatinib each showed strong, dose-dependent cytotoxic effects, with Lapatinib demonstrating the greatest potency. Bevacizumab alone exhibited minimal cytotoxic activity, but when combined with Sorafenib or Lapatinib it significantly enhanced their effects, even at concentrations that were only partially effective individually. The Lapatinib–Bevacizumab combination produced the most potent inhibition of cell viability, comparable to high-dose monotherapy.
Conclusions
These findings suggest that combining kinase inhibitors with Bevacizumab may enhance antitumor activity, allow the use of lower drug doses, and overcome resistance, representing a promising therapeutic strategy for medullary thyroid carcinoma that warrants further investigation in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Sivas Numune State Hospital, 58060 Sivas, Türkiye.
- Department of Gastroenterology, Bodrum Memorial Hospital, 48400 Bodrum, Türkiye.
ORCID-Profile: Gülşah Altun, Özlem Yönem
Zitieren
APA
Altun, G., & Yönem, Ö. (2025). Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells. Current Oncology. https://doi.org/10.3390/curroncol32110607
Vancouver
Altun G, Yönem Ö. Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells. Current Oncology. 2025. doi:10.3390/curroncol32110607
BibTeX
@article{Altun2025,
author = {Altun, Gülşah and Yönem, Özlem},
title = {Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32110607}
}
EUVIMED